ALB and hepatocellular carcinoma: The PROSASH and PROSASH-II model, which consisted of serum albumin, bilirubin, AFP, macrovascular invasion, extrahepatic spread, and largest tumor size, could predict the survival of patients with HCC treated with sorafenib (26, 27).